• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by BioLife Solutions Inc. (Amendment)

    1/24/24 4:16:40 PM ET
    $BLFS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $BLFS alert in real time by email
    SC 13G/A 1 BLFS_SC13GA1_2024.htm SCHEDULE 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G
    Under the Securities Exchange Act of 1934

    (AMENDMENT NO. 1)

    BIOLIFE SOLUTIONS, INC.
    (Name of Issuer)

    COMMON STOCK, PAR VALUE $0.001 PER SHARE
    (Title of Class of Securities)

    09062W204
    (CUSIP Number)

    DECEMBER 31, 2023
    (Date of event which requires filing of this statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

         o Rule 13d-1(b)

         þ Rule 13d-1(c)

         o Rule 13d-1(d)

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the notes).



                         
    CUSIP No.
     
    09062W204

    SCHEDULE 13G

    Page  
    2
      of   
    11

    1
     NAMES OF REPORTING PERSONS
     
     Integrated Core Strategies (US) LLC
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   o
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     2,404,862
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     2,404,862
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     2,404,862
    10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     5.3%
    12 TYPE OF REPORTING PERSON

     OO


                         
    CUSIP No.
     
    09062W204

    SCHEDULE 13G

    Page  
    3
      of   
    11

    1
     NAMES OF REPORTING PERSONS
     
     Millennium Management LLC
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   o
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     2,412,650
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     2,412,650
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     2,412,650
    10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     5.4%
    12 TYPE OF REPORTING PERSON

     
    OO


                         
    CUSIP No.
     
    09062W204

    SCHEDULE 13G

    Page  
    4
      of   
    11

    1
     NAMES OF REPORTING PERSONS
     
     Millennium Group Management LLC
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   o
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     2,412,650
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     2,412,650
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     2,412,650
    10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     5.4%
    12 TYPE OF REPORTING PERSON

     
    OO


                         
    CUSIP No.
     
    09062W204

    SCHEDULE 13G

    Page  
    5
      of   
    11

    1
     NAMES OF REPORTING PERSONS
     
     Israel A. Englander
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   o
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     2,412,650
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     2,412,650
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     2,412,650
    10
     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     5.4%
    12
     TYPE OF REPORTING PERSON

     IN

                         
    CUSIP No.
     
    09062W204

     SCHEDULE 13G

    Page  
    6
      of   
    11
     
    Item 1.    
     
    (a) Name of Issuer:
     
       
     
      BioLife Solutions, Inc.
     
       
     
    (b) Address of Issuer’s Principal Executive Offices:
     
       
     
     

    3303 Monte Villa Parkway, Suite 310
    Bothell, Washington 98021

         
    Item 2.
    (a) Name of Person Filing:
     
    (b) Address of Principal Business Office:
     
    (c) Citizenship:
         
     
      Integrated Core Strategies (US) LLC
    c/o Millennium Management LLC
    399 Park Avenue
    New York, New York 10022
    Citizenship: Delaware
     
       
     
      Millennium Management LLC
    399 Park Avenue
    New York, New York 10022
    Citizenship: Delaware
     
       
     
      Millennium Group Management LLC
    399 Park Avenue
    New York, New York 10022
    Citizenship: Delaware
     
       
     
      Israel A. Englander
    c/o Millennium Management LLC
    399 Park Avenue
    New York, New York 10022
    Citizenship: United States
     
       
      (d) Title of Class of Securities:
    common stock, par value $0.001 per share ("Common Stock")
     
      (e) CUSIP Number:
    09062W204
     
     

    Item 3.  If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b), check whether the person filing is a:

     
      (a)   o   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
                 
     
      (b)   o   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
                 
     
      (c)   o   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
                 
     
      (d)   o   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
                 
     
      (e)   o   An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
                 
     
      (f)   o    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

                         
    CUSIP No.
     
    09062W204

     SCHEDULE 13G

    Page  
    7
      of   
    11
                 
     
      (g)   o   A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
                 
     
      (h)   o   A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
                 
     
      (i)   o   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
                 
     
      (j)   o   Group, in accordance with §240.13d-1(b)(1)(ii)(J).

    Item 4. Ownership

       Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a) Amount Beneficially Owned:

       See response to Item 9 on each cover page.

       The reporting persons ceased to be beneficial owners of more than 5% of the outstanding Common Stock as of January 18, 2024.

    (b) Percent of Class:   

       See response to Item 11 on each cover page.

     (c) Number of shares as to which such person has:

    (i) Sole power to vote or to direct the vote

       See response to Item 5 on each cover page.


                         
    CUSIP No.
     
    09062W204

     SCHEDULE 13G

    Page  
    8
      of   
    11

    (ii) Shared power to vote or to direct the vote

       See response to Item 6 on each cover page.

    (iii) Sole power to dispose or to direct the disposition of

       See response to Item 7 on each cover page.

    (iv) Shared power to dispose or to direct the disposition of

       See response to Item 8 on each cover page.

       The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.

    Item 5. Ownership of Five Percent or Less of a Class

       If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following þ .

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

        Not applicable.

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

        Not applicable.

    Item 8. Identification and Classification of Members of the Group

        See Exhibit I.

    Item 9. Notice of Dissolution of Group

        Not applicable.

    Item 10. Certification 

       By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


                         
    CUSIP No.
     
    09062W204

    SCHEDULE 13G

    Page  
    9
      of   
    11

    Exhibits:

    Exhibit I:  Joint Filing Agreement, dated as of January 23, 2024, by and among Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.


                         
    CUSIP No.
     
    09062W204

    SCHEDULE 13G

    Page  
    10
      of   
    11
                         
         

    SIGNATURE

                 

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

    Dated: January 23, 2024

    INTEGRATED CORE STRATEGIES (US) LLC

    By: Integrated Holding Group LP,
           its Managing Member

    By: Millennium Management LLC,
           its General Partner

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    MILLENNIUM MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    MILLENNIUM GROUP MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    /s/ Israel A. Englander

    Israel A. Englander



                         
    CUSIP No.
     
    09062W204

    SCHEDULE 13G

    Page  
    11
      of   
    11
                         
          EXHIBIT I              
                         
          JOINT FILING AGREEMENT              

    This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Common Stock, par value $0.001 per share, of BioLife Solutions, Inc. will be filed on behalf of each of the persons and entities named below in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

    Dated: January 23, 2024

    INTEGRATED CORE STRATEGIES (US) LLC

    By: Integrated Holding Group LP,
           its Managing Member

    By: Millennium Management LLC,
           its General Partner

    By: /s/ Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    MILLENNIUM MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    MILLENNIUM GROUP MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    /s/ Israel A. Englander

    Israel A. Englander


    Get the next $BLFS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BLFS

    DatePrice TargetRatingAnalyst
    7/22/2025$30.00Overweight
    Stephens
    9/30/2024$29.00Buy
    H.C. Wainwright
    4/4/2024$22.00Buy
    Jefferies
    7/11/2023$29.00Buy
    Craig Hallum
    4/25/2022$28.00Perform → Outperform
    Oppenheimer
    10/19/2021$61.00Buy
    B. Riley Securities
    10/15/2021$64.00Outperform
    Cowen
    8/13/2021$50.00 → $60.00Overweight
    Keybanc
    More analyst ratings

    $BLFS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BioLife Solutions Reports Second Quarter 2025 Financial Results

    Cell Processing revenue of $23.0 million, up 28% over Q2 2024 GAAP gross margin of 62% and non-GAAP adjusted gross margin of 65% GAAP net loss of $15.8 million, inclusive of a non-cash $15.5 million IPR&D expense, and non-GAAP adjusted EBITDA of $6.1 million or 24% of revenue Raises full-year 2025 revenue guidance to $100.0 million - $103.0 million, and full-year 2025 Cell Processing revenue guidance to $91.0 million - $93.0 million Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash., Aug. 7, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene th

    8/7/25 4:03:00 PM ET
    $BLFS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BioLife Solutions Makes Strategic Investment in Pluristyx

    BOTHELL, Wash., July 28, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced that as part of a larger round of financing it has purchased $2 million of convertible notes in Pluristyx, Inc. ("Pluristyx"), a Seattle based developer of innovative induced pluripotent stem cell (iSPC) based products for cell therapy developers. BioLife also entered into a separate agreement which provides a board observer seat, and certain rights related to any potential future acquisition of Pluristyx.

    7/28/25 8:05:00 AM ET
    $BLFS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BioLife Solutions to Report Second Quarter 2025 Financial Results and Business Update on August 7, 2025

    BOTHELL, Wash., July 24, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the Company's second quarter 2025 financial results will be released after market close on Thursday, August 7, 2025. The Company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) that day. Management will provide an overview of the Company's financial results and give a general business update. To access the webcast, log onto the Investor Rel

    7/24/25 4:05:00 PM ET
    $BLFS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $BLFS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Casdin Partners Master Fund, L.P. sold $11,300,000 worth of shares (500,000 units at $22.60) (SEC Form 4)

    4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)

    8/13/25 6:43:14 PM ET
    $BLFS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Technology Officer Werner Sean sold $23,660 worth of shares (1,115 units at $21.22), decreasing direct ownership by 4% to 26,495 units (SEC Form 4)

    4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)

    7/22/25 5:33:30 PM ET
    $BLFS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Human Resources Officer Aebersold Sarah sold $4,409 worth of shares (198 units at $22.27), decreasing direct ownership by 0.25% to 78,523 units (SEC Form 4)

    4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)

    7/9/25 5:54:44 PM ET
    $BLFS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $BLFS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $BLFS
    SEC Filings

    View All

    $BLFS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Stephens resumed coverage on BioLife Solutions with a new price target

    Stephens resumed coverage of BioLife Solutions with a rating of Overweight and set a new price target of $30.00

    7/22/25 7:51:31 AM ET
    $BLFS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    H.C. Wainwright initiated coverage on BioLife Solutions with a new price target

    H.C. Wainwright initiated coverage of BioLife Solutions with a rating of Buy and set a new price target of $29.00

    9/30/24 7:39:39 AM ET
    $BLFS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Jefferies initiated coverage on BioLife Solutions with a new price target

    Jefferies initiated coverage of BioLife Solutions with a rating of Buy and set a new price target of $22.00

    4/4/24 7:31:02 AM ET
    $BLFS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 10-Q filed by BioLife Solutions Inc.

    10-Q - BIOLIFE SOLUTIONS INC (0000834365) (Filer)

    8/7/25 4:22:52 PM ET
    $BLFS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BioLife Solutions Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - BIOLIFE SOLUTIONS INC (0000834365) (Filer)

    8/7/25 4:10:06 PM ET
    $BLFS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form DEFA14A filed by BioLife Solutions Inc.

    DEFA14A - BIOLIFE SOLUTIONS INC (0000834365) (Filer)

    7/8/25 4:58:42 PM ET
    $BLFS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Casdin Partners Master Fund, L.P. bought $10,374,976 worth of shares (927,165 units at $11.19) (SEC Form 4)

    4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)

    10/23/23 5:42:32 PM ET
    $BLFS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $BLFS
    Financials

    Live finance-specific insights

    View All

    BioLife Solutions Reports Second Quarter 2025 Financial Results

    Cell Processing revenue of $23.0 million, up 28% over Q2 2024 GAAP gross margin of 62% and non-GAAP adjusted gross margin of 65% GAAP net loss of $15.8 million, inclusive of a non-cash $15.5 million IPR&D expense, and non-GAAP adjusted EBITDA of $6.1 million or 24% of revenue Raises full-year 2025 revenue guidance to $100.0 million - $103.0 million, and full-year 2025 Cell Processing revenue guidance to $91.0 million - $93.0 million Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash., Aug. 7, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene th

    8/7/25 4:03:00 PM ET
    $BLFS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BioLife Solutions to Report Second Quarter 2025 Financial Results and Business Update on August 7, 2025

    BOTHELL, Wash., July 24, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the Company's second quarter 2025 financial results will be released after market close on Thursday, August 7, 2025. The Company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) that day. Management will provide an overview of the Company's financial results and give a general business update. To access the webcast, log onto the Investor Rel

    7/24/25 4:05:00 PM ET
    $BLFS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BioLife Solutions Reports First Quarter 2025 Financial Results

    Cell Processing revenue of $21.6 million, up 33% over Q1 2024 GAAP gross margin of 63% and non-GAAP adjusted gross margin of 66% GAAP net loss of $0.4 million and non-GAAP adjusted EBITDA of $5.7 million or 24% of revenue Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash., May 8, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy ("CGT") market, announces financial results for the three months ended March 31, 2025. Roderi

    5/8/25 4:03:00 PM ET
    $BLFS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $BLFS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by BioLife Solutions Inc. (Amendment)

    SC 13G/A - BIOLIFE SOLUTIONS INC (0000834365) (Subject)

    2/13/24 5:00:45 PM ET
    $BLFS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by BioLife Solutions Inc. (Amendment)

    SC 13G/A - BIOLIFE SOLUTIONS INC (0000834365) (Subject)

    1/24/24 4:16:40 PM ET
    $BLFS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13D/A filed by BioLife Solutions Inc. (Amendment)

    SC 13D/A - BIOLIFE SOLUTIONS INC (0000834365) (Subject)

    10/24/23 4:29:23 PM ET
    $BLFS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $BLFS
    Leadership Updates

    Live Leadership Updates

    View All

    BioLife Solutions Appoints Cathy Coste as Director and Audit Committee Chair

    BOTHELL, Wash., March 18, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the appointment of Cathy Coste to its board of directors, increasing board membership to seven. Ms. Coste will serve as chair of the audit committee, replacing Joydeep Goswami, who will remain a company director and member of the audit committee. "Cathy is a highly qualified financial professional with substantial expertise in audits, risk an

    3/18/25 8:30:00 AM ET
    $BLFS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BioLife Solutions Appoints Tony J. Hunt to its Board of Directors

    BOTHELL, Wash., Dec. 16, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the appointment of Tony J. Hunt, Executive Chairman of Repligen Corporation (NASDAQ:RGEN) and a recognized leader in bioprocessing innovation, to its board of directors effective January 2, 2025. His appointment increases board membership to six. "Tony is highly respected in the life sciences industry with decades of accomplishments, and it is

    12/16/24 8:11:00 AM ET
    $BLFS
    $RGEN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    BioLife Solutions Appoints Cell Therapy Executive Timothy L. Moore to its Board of Directors

    Industry veteran brings extensive technical operations scale-up experience and extreme fluency in cell therapy tools and services selection process BOTHELL, Wash., Aug. 25, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies ("CGT") and the broader biopharma markets, today announced the appointment of Timothy L. Moore to its board of directors, increasing board membership to six. Moore brings more than 30 years of broad-based leadership experience in biopharmaceutical manufacturing and operations.

    8/25/22 8:03:00 AM ET
    $BLFS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care